Brief: Venus Medtech Hangzhou Says Transcatheter Pulmonic Valve Replacement Received Approval Of NMPA Of PRC
12/07/2022 11:21
July 12 (Reuters) - Venus Medtech Hangzhou Inc 2500.HK :
* TRANSCATHETER PULMONIC VALVE REPLACEMENT RECEIVED APPROVAL
OF
NMPA OF PRC
Further company coverage: 2500.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Venus Medtech (Hangzhou)
See all newsBrief: Venus Medtech Hangzhou To Issue 184.5 Million Shares And HK$379.7 Million Convertible Bonds
Brief: Venus Medtech Hangzhou Says Six-Month Revenue Rmb135.5 Million
Brief: Venus Medtech Hangzhou Says Liqiao Ma Resigns As Executive Director
Brief: Venus Medtech Hangzhou Logs FY Revenue RMB 306.8 Mln
Brief: Venus Medtech Says Unaware Of Any Info Needing Disclosure To Avoid False Market